Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- EIKN
- Price
- 15.72
- Stock movement up
- +0.67 (4.45%)
- Company name
- Eikon Therapeutics, Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- 1.35B
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
EIKN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | -1.20 |
| FCF per share (TTM) | -1.17 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -67.78M |
| Net income (TTM) | -64.92M |
| EPS (TTM) | -1.20 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 104.87M |
| Net receivables | 0.00 |
| Total current assets | 390.50M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 284.98M |
| Total assets | 649.03M |
| Accounts payable | 4.28M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 44.94M |
| Total liabilities | 1.45B |
| Shareholder's equity | -804.35M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -23.74M |
| Capital expenditures (TTM) | 39.52M |
| Free cash flow (TTM) | -63.26M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -10.00% |
| Return on Invested Capital | 8.07% |
| Cash Return on Invested Capital | 7.86% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 15.35 |
| Daily high | 16.25 |
| Daily low | 15.25 |
| Daily Volume | 482K |
| All-time high | 15.72 |
| 1y analyst estimate | - |
| Beta | - |
| EPS (TTM) | -1.20 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| EIKN | S&P500 | |
| Current price drop from All-time high | -0.41% | -0.51% |
| Highest price drop | -6.60% | -56.47% |
| Date of highest drop | 10 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -0.88% | -10.84% |
| Avg time to new high | 1 days | 12 days |
| Max time to new high | 3 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Employees
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner